<SEC-DOCUMENT>0000921895-25-002083.txt : 20250804
<SEC-HEADER>0000921895-25-002083.hdr.sgml : 20250804
<ACCEPTANCE-DATETIME>20250804192457
ACCESSION NUMBER:		0000921895-25-002083
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250804
DATE AS OF CHANGE:		20250804

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80136
		FILM NUMBER:		251182248

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lazar David E.
		CENTRAL INDEX KEY:			0001932843
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		44, TOWER 100, THE TOWERS
		STREET 2:		WINSTON CHURCHILL, PAITILLA
		CITY:			PANAMA CITY
		STATE:			R1
		ZIP:			07196
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Lazar David E. -->
          <cik>0001932843</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <dateOfEvent>07/30/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001130166</issuerCIK>
        <issuerCUSIP>23254L801</issuerCUSIP>
        <issuerName>Cyclacel Pharmaceuticals, Inc.</issuerName>
        <address>
          <com:street1>200 CONNELL DRIVE</com:street1>
          <com:street2>SUITE 1500</com:street2>
          <com:city>BERKELEY HEIGHTS</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07922</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>DAVID E. LAZAR</personName>
          <personPhoneNum>646-768-8417</personPhoneNum>
          <personAddress>
            <com:street1>44, Tower 100, The Towers</com:street1>
            <com:street2>Winston Churchill</com:street2>
            <com:city>Panama City</com:city>
            <com:stateOrCountry>R1</com:stateOrCountry>
            <com:zipCode>07196</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001932843</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Lazar David E.</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>L3</citizenshipOrOrganization>
        <soleVotingPower>129629.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>129629.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>129629.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>8.18</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, $0.001 par value</securityTitle>
        <issuerName>Cyclacel Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>200 CONNELL DRIVE</com:street1>
          <com:street2>SUITE 1500</com:street2>
          <com:city>BERKELEY HEIGHTS</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07922</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.</commentText>
      </item1>
      <item4>
        <transactionPurpose>Item 4 is hereby amended to add the following:

The Reporting Person resigned as Chief Executive Officer of the Issuer effective as of April 2, 2025.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Item 5(a) is hereby amended and restated as follows:

The aggregate percentage of Shares owned by the Reporting Person is based upon 1,583,965 shares of Common Stock outstanding as of July 10, 2025, as reported in the Issuer's Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission on July 30, 2025.

As of the close of business on August 1, 2025, the Reporting Person beneficially owned 129,629 Shares.

Percentage: Approximately 8.18%</percentageOfClassSecurities>
        <numberOfShares>Item 5(b) is hereby amended and restated as follows:

1. Sole power to vote or direct vote: 129,629
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 129,629
4. Shared power to dispose or direct the disposition: 0</numberOfShares>
        <transactionDesc>Item 5(c) is hereby amended and restated as follows:

The transactions in the Shares by the Reporting Persons during the past sixty days are set forth in more detail in Exhibit 1 and are incorporated herein by reference.</transactionDesc>
      </item5>
      <item6>
        <contractDescription>Item 6 is hereby amended to add the following:

The number Shares owned by the Reporting Person in this Amendment No. 1 is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").

On February 26, 2025, the Reporting Person (i) converted his shares of Preferred Stock into Shares of common stock of the Issuer pursuant to the conversion terms set forth above and (ii) sold 194,628,820 shares of Common Stock to a third party investor in a private transaction (the "February Sale"). Due to a ministerial error, the original Schedule 13D filed by the Reporting Person on February 28, 2025 inadvertently reported that the Reporting Person retained a total of 354,738 shares of Series D Preferred Stock following the February Sale, which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>1 - Transactions in the Securities</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Lazar David E.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ David E. Lazar</signature>
          <title>David E. Lazar</title>
          <date>08/04/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>ex1to13da112227019_080425.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">Exhibit 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><U>Transactions in the Securities of the
Issuer During the Past Sixty Days</U></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-top: 2.65pt; padding-right: 2.75pt; padding-left: 2.75pt; text-align: center">Shares of Common Stock Sold</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-top: 2.65pt; padding-right: 2.75pt; padding-left: 2.75pt; text-align: center">Price Per Share</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-top: 2.65pt; padding-right: 2.75pt; padding-left: 2.75pt; text-align: center">Date of Sale</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">6,750 </TD>
    <TD STYLE="width: 33%; padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">$12.36</TD>
    <TD STYLE="width: 33%; padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">7/30/2025</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">15,000</TD>
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">$11.68</TD>
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">7/31/2025</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">10.22</TD>
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">$10.22</TD>
    <TD STYLE="padding-top: 2.65pt; padding-bottom: 1.5pt; text-align: center">8/1/2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
